FDA Approves Genentech's Inavolisib Triplet with Companion Diagnostic

The FDA's October 10, 2024 approval of inavolisib (Itovebi, Genentech) in combination with palbociclib and fulvestrant carries a structural implication that extends beyond oncology labeling: the simultaneous approval of the FoundationOne Liquid CDx as a companion diagnostic device establishes a co-dependent regulatory model that directly affects labeling strategy, manufacturing coordination with diagnostics partners, and post-market surveillance obligations.

Regulatory affairs leads should note that patient eligibility is gated by an FDA-approved test, meaning the companion diagnostic is not optional infrastructure but a condition of use embedded in the indication. The approved population is adults with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer whose disease progressed during or within 12 months of completing adjuvant endocrine therapy, with no prior systemic therapy for advanced disease.

Efficacy data from the INAVO120 trial (NCT04191499), a randomized, double-blind, placebo-controlled, multicenter study in 325 patients, underpinned the submission. Median progression-free survival reached 15.0 months in the inavolisib arm versus 7.3 months in the placebo arm (HR 0.43; 95% CI: 0.32, 0.59; p<0.0001). Objective response rate was 58% versus 25%, and median duration of response was 18.4 versus 9.6 months. An interim overall survival analysis at 63% information fraction did not reach statistical significance but was considered supportive of the benefit-risk assessment (HR 0.64; 95% CI: 0.43, 0.97).

The dosing regimen, inavolisib 9 mg orally once daily, palbociclib 125 mg orally once daily on a 21-days-on/7-days-off cycle, and fulvestrant 500 mg intramuscularly per a standard 28-day schedule, introduces a multi-agent, multi-route administration profile that QA directors will need to account for in deviation management and labeling reconciliation. The adverse reaction profile, which includes decreased neutrophils, increased fasting glucose, stomatitis, and diarrhea in 20% or more of patients, has direct relevance to pharmacovigilance reporting structures and risk management planning.

The review was conducted under Project Orbis, the FDA Oncology Center of Excellence's framework for concurrent international submission and review. Collaborating agencies included Australia's TGA, Health Canada, and Switzerland's Swissmedic, a multi-jurisdictional review pathway that may require harmonized labeling considerations across markets where parallel approvals follow.

Post-market surveillance obligations tied to the FoundationOne Liquid CDx companion diagnostic will be a measurable checkpoint for QA and regulatory teams as the triplet regimen moves into commercial supply chains.

Source: FDA Drugs, What's New RSS Feed via fda.gov, November 7, 2026.